Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
740000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise of the 19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
New shares 740,000 shares / Treasury shares transferred 0 shares
EVO FUND (issued on 8 August 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+1.70%Rate of increase
54,332,640 shares55,072,640Shares
1.7% (exercise ratio subject to exercise restrictions) / The ratio of 740,000 shares delivered during the month to the 54,332,640 issued shares as of the end of the previous month is not disclosed
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥91, ¥88, ¥86, ¥85 and ¥80 (exercise prices on the respective exercise dates in April 2026). The floor under the adjustment clause is Not disclosed
Number of Stock Acquisition Rights
Total issued: 110,000 rights; exercised during the applicable month: 7,400 rights; unexercised as of the end of the applicable month: 102,600 rights
Procedures under the Corporate Code of Conduct
As the status of compliance with the exercise restrictions under Article 434 of the Listing Regulations, the disclosure states that 740,000 shares were delivered across all series, the number of listed shares as of the payment date for the issuance was 44,613,940, and the exercise ratio subject to the exercise restrictions was 1.7%
Most recent equity financing
Timing 8 August 2025 / Type Issuance of the 18th through 20th Series Stock Acquisition Rights, including the 19th Series Stock Acquisition Rights (with exercise price adjustment clause) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise of the 19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | New shares 740,000 shares / Treasury shares transferred 0 shares |
| Intended allottee | EVO FUND (issued on 8 August 2025) |
| Dilution Rate | 1.7% (exercise ratio subject to exercise restrictions) / The ratio of 740,000 shares delivered during the month to the 54,332,640 issued shares as of the end of the previous month is not disclosed |
| Total number of issued shares | 54,332,640 shares (as of the end of the month preceding the applicable month, including 23,824 treasury shares) → 55,072,640 shares (assuming the number of shares at the end of the previous month plus the number of shares delivered during the applicable month) |
| Exercise price | ¥91, ¥88, ¥86, ¥85 and ¥80 (exercise prices on the respective exercise dates in April 2026). The floor under the adjustment clause is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 110,000 rights; exercised during the applicable month: 7,400 rights; unexercised as of the end of the applicable month: 102,600 rights |
| Procedures under the Corporate Code of Conduct | As the status of compliance with the exercise restrictions under Article 434 of the Listing Regulations, the disclosure states that 740,000 shares were delivered across all series, the number of listed shares as of the payment date for the issuance was 44,613,940, and the exercise ratio subject to the exercise restrictions was 1.7% |
| Most recent equity financing | Timing 8 August 2025 / Type Issuance of the 18th through 20th Series Stock Acquisition Rights, including the 19th Series Stock Acquisition Rights (with exercise price adjustment clause) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the 19th Series Stock Acquisition Rights in April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.